We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Plastic Chip Identifies DNA Sequences in Drop of Blood

By LabMedica International staff writers
Posted on 09 May 2012
A small plastic chip developed using nanotechnology can determine whether a patient is resistant to cancer drugs or has diseases such as malaria. More...
The chip can also pinpoint infectious diseases in a herd of cattle.

The technology that uses the plastic chip can perform 20 genetic tests from a single drop of blood. The innovation has earned Aquila Diagnostic Systems (Edmonton, Canada), a finalist nod for this year’s TEC (Edmonton, Canada) NanoVenturePrize award. Aquila Diagnostics is a nano startup originating from the University of Alberta (U of A; Edmonton, Canada).

Dubbed the Domino technology, it employs miniaturized polymerase chain reaction (PCR) technology to amplify and detect targeted sequences of DNA in a form that fits on a plastic chip the size of two postage stamps. The chip contains 20 gel posts--each the size of a pinhead--capable of identifying sequences of DNA in a single drop of blood. The Domino has been used in several recently published studies, showing similar accuracy to centralized labs.

A metal cube the size of a toaster, with the small plastic chip at its core, created at the University of Alberta is capable of performing the same genetic tests as most fully equipped modern laboratories--and in a fraction of the time. Along with its versatility, two key selling points are affordability and portability, with each portable box expected to cost about USD 5,000 and each chip a few dollars, according to Aquila president David Alton. It is also designed to be easy to use and rugged for use in the field.

Each post performs its own genetic test, meaning that it is possible not only to find out whether an individual has malaria, but also to determine the type of malaria and whether the person’s DNA makes him resistant to certain antimalarial drugs. It takes less than an hour to process one chip, making it possible to screen large populations in a short time.

“We [are] basically replacing millions of dollars of equipment in a conventional, consolidated lab with something that costs pennies to produce and is field portable so that it can be taken where needed. That [is] where this technology shines,” said Jason Acker, an associate professor of laboratory medicine and pathology at the University of Alberta and chief technology officer with Aquila.

Aquila’s relationship with the U of A and its business relationship with TEC Edmonton helped the company to license and patent Domino. TEC Edmonton is a joint venture between the U of A and Edmonton Economic Development Corp. It has resources and expertise to help startups in the early stages of operations.

Related Links:

Aquila Diagnostic Systems
TEC
University of Alberta



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.